You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Details for Patent: 8,911,786

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,911,786 protect, and when does it expire?

Patent 8,911,786 protects FYARRO and is included in one NDA.

This patent has sixty-eight patent family members in twenty-three countries.

Summary for Patent: 8,911,786

Title:	Nanoparticle comprising rapamycin and albumin as anticancer agent
Abstract:	The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
Inventor(s):	Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA), Trieu; Vuong (Calabasas, CA)
Assignee:	Abraxis Bioscience, LLC (Los Angeles, CA)
Application Number:	12/530,188
Patent Claim Types: see list of patent claims	Use; Composition; Device; Dosage form;

Drugs Protected by US Patent 8,911,786

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Aadi	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA)	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,911,786

PCT Information
PCT Filed	March 07, 2008	PCT Application Number:	PCT/US2008/003096
PCT Publication Date:	September 12, 2008	PCT Publication Number:	WO2008/109163

International Family Members for US Patent 8,911,786

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2008223334	⤷ Try a Trial
Brazil	PI0808635	⤷ Try a Trial
Canada	2680207	⤷ Try a Trial
Canada	3006137	⤷ Try a Trial
Canada	3201293	⤷ Try a Trial
China	101730526	⤷ Try a Trial
China	104814930	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.